SidaGhanaV1, Istex, Corpus, bibRecord, 000830

Protective effect of HLA‐B57 on HCV genotype 2 infection in a West African population

Identifieur interne : 000830 ( Istex/Corpus ); précédent : 000829; suivant : 000831

Protective effect of HLA‐B57 on HCV genotype 2 infection in a West African population

Auteurs : Wing Chia-Ming Chuang ; Francis Sarkodie ; Colin J. Brown ; Shirley Owusu-Ofori ; Juliette Brown ; Chengyao Li ; Cristina Navarrete ; Paul Klenerman ; Jean-Pierre Allain

Source :

Journal of Medical Virology [ 0146-6615 ] ; 2007-06.

RBID : ISTEX:95373D3160E2A7717E344A8120A43D3C167CE4F4

English descriptors

Abstract

Recovery from Hepatitis C virus (HCV) infection is considered infrequent (<20%) in western populations but reaches 50% in West Africa where genotype 2 infection is predominant. To investigate the role of cellular immune responses and host genetics in this phenomenon, samples from 104 Ghanaian blood donors reactive with anti‐HCV assays were collected between 2000 and 2005. HCV antibody was confirmed by Western blot using genotype 2 recombinant core, E2 and NS3 proteins. Viral load and genotype were determined. Samples were stratified into 37 chronic, 35 recovered infections and 32 false positive. Eighty‐one percentage of subjects with chronic infection (RNA positive) carried genotype 2 HCV. Cellular immune response was investigated in 35 frozen peripheral blood mononuclear cell (PBMC) samples suitable for interferon‐gamma ELISPOT assay. Twelve out of 24 confirmed recovered, 1 out of 5 chronically infected and none of the 6 false‐positive controls reacted to recombinant proteins. HLA‐A, ‐B and ‐DR types were determined by DNA methodology. HLA‐B*57 was significantly more frequent in the group which had recovered from HCV infection compared with chronically infected subjects (P = 0.0053, OR = 8.02). In conclusion, it is hypothesized that the dominance of genotype 2 HCV strains may be an important factor explaining the high rate of recovery from HCV infections in Ghana via an efficient contribution of HLA‐B*57 which is relatively frequent in the population. J. Med. Virol. 79: 724–733, 2007. © 2007 Wiley‐Liss, Inc.

Url:

https://api.istex.fr/document/95373D3160E2A7717E344A8120A43D3C167CE4F4/fulltext/pdf

DOI: 10.1002/jmv.20848

Links to Exploration step

ISTEX:95373D3160E2A7717E344A8120A43D3C167CE4F4

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Protective effect of HLA‐B57 on HCV genotype 2 infection in a West African population</title>
<author><name sortKey="Chuang, Wing Chia Ing" sort="Chuang, Wing Chia Ing" uniqKey="Chuang W" first="Wing Chia-Ming" last="Chuang">Wing Chia-Ming Chuang</name>
<affiliation><mods:affiliation>Department of Haematology, University of Cambridge, Cambridge, UK</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Sarkodie, Francis" sort="Sarkodie, Francis" uniqKey="Sarkodie F" first="Francis" last="Sarkodie">Francis Sarkodie</name>
<affiliation><mods:affiliation>Transfusion Medicine Unit, Department of Medicine, Komfo Anokye Teaching Hospital, Kumasi, Ghana</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Brown, Colin J" sort="Brown, Colin J" uniqKey="Brown C" first="Colin J." last="Brown">Colin J. Brown</name>
<affiliation><mods:affiliation>Department of Histocompatibility & Immunogenetics, National Blood Service, Colindale, London, UK</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Owusu Fori, Shirley" sort="Owusu Fori, Shirley" uniqKey="Owusu Fori S" first="Shirley" last="Owusu-Ofori">Shirley Owusu-Ofori</name>
<affiliation><mods:affiliation>Transfusion Medicine Unit, Department of Medicine, Komfo Anokye Teaching Hospital, Kumasi, Ghana</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Brown, Juliette" sort="Brown, Juliette" uniqKey="Brown J" first="Juliette" last="Brown">Juliette Brown</name>
<affiliation><mods:affiliation>Department of Histocompatibility & Immunogenetics, National Blood Service, Colindale, London, UK</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Li, Chengyao" sort="Li, Chengyao" uniqKey="Li C" first="Chengyao" last="Li">Chengyao Li</name>
<affiliation><mods:affiliation>National Blood Service, Cambridge, UK</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Navarrete, Cristina" sort="Navarrete, Cristina" uniqKey="Navarrete C" first="Cristina" last="Navarrete">Cristina Navarrete</name>
<affiliation><mods:affiliation>Department of Histocompatibility & Immunogenetics, National Blood Service, Colindale, London, UK</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Klenerman, Paul" sort="Klenerman, Paul" uniqKey="Klenerman P" first="Paul" last="Klenerman">Paul Klenerman</name>
<affiliation><mods:affiliation>Nuffield Department of Medicine, University of Oxford, Oxford, UK</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Allain, Jean Ierre" sort="Allain, Jean Ierre" uniqKey="Allain J" first="Jean-Pierre" last="Allain">Jean-Pierre Allain</name>
<affiliation><mods:affiliation>Department of Haematology, University of Cambridge, Cambridge, UK</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>Division of Transfusion Medicine, Cambridge Blood Centre, Long Road, Cambridge CB2 2PT, UK.===</mods:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:95373D3160E2A7717E344A8120A43D3C167CE4F4</idno>
<date when="2007" year="2007">2007</date>
<idno type="doi">10.1002/jmv.20848</idno>
<idno type="url">https://api.istex.fr/document/95373D3160E2A7717E344A8120A43D3C167CE4F4/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000830</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000830</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Protective effect of HLA‐B57 on HCV genotype 2 infection in a West African population</title>
<author><name sortKey="Chuang, Wing Chia Ing" sort="Chuang, Wing Chia Ing" uniqKey="Chuang W" first="Wing Chia-Ming" last="Chuang">Wing Chia-Ming Chuang</name>
<affiliation><mods:affiliation>Department of Haematology, University of Cambridge, Cambridge, UK</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Sarkodie, Francis" sort="Sarkodie, Francis" uniqKey="Sarkodie F" first="Francis" last="Sarkodie">Francis Sarkodie</name>
<affiliation><mods:affiliation>Transfusion Medicine Unit, Department of Medicine, Komfo Anokye Teaching Hospital, Kumasi, Ghana</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Brown, Colin J" sort="Brown, Colin J" uniqKey="Brown C" first="Colin J." last="Brown">Colin J. Brown</name>
<affiliation><mods:affiliation>Department of Histocompatibility & Immunogenetics, National Blood Service, Colindale, London, UK</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Owusu Fori, Shirley" sort="Owusu Fori, Shirley" uniqKey="Owusu Fori S" first="Shirley" last="Owusu-Ofori">Shirley Owusu-Ofori</name>
<affiliation><mods:affiliation>Transfusion Medicine Unit, Department of Medicine, Komfo Anokye Teaching Hospital, Kumasi, Ghana</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Brown, Juliette" sort="Brown, Juliette" uniqKey="Brown J" first="Juliette" last="Brown">Juliette Brown</name>
<affiliation><mods:affiliation>Department of Histocompatibility & Immunogenetics, National Blood Service, Colindale, London, UK</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Li, Chengyao" sort="Li, Chengyao" uniqKey="Li C" first="Chengyao" last="Li">Chengyao Li</name>
<affiliation><mods:affiliation>National Blood Service, Cambridge, UK</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Navarrete, Cristina" sort="Navarrete, Cristina" uniqKey="Navarrete C" first="Cristina" last="Navarrete">Cristina Navarrete</name>
<affiliation><mods:affiliation>Department of Histocompatibility & Immunogenetics, National Blood Service, Colindale, London, UK</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Klenerman, Paul" sort="Klenerman, Paul" uniqKey="Klenerman P" first="Paul" last="Klenerman">Paul Klenerman</name>
<affiliation><mods:affiliation>Nuffield Department of Medicine, University of Oxford, Oxford, UK</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Allain, Jean Ierre" sort="Allain, Jean Ierre" uniqKey="Allain J" first="Jean-Pierre" last="Allain">Jean-Pierre Allain</name>
<affiliation><mods:affiliation>Department of Haematology, University of Cambridge, Cambridge, UK</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>Division of Transfusion Medicine, Cambridge Blood Centre, Long Road, Cambridge CB2 2PT, UK.===</mods:affiliation>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j" type="main">Journal of Medical Virology</title>
<title level="j" type="alt">JOURNAL OF MEDICAL VIROLOGY</title>
<idno type="ISSN">0146-6615</idno>
<idno type="eISSN">1096-9071</idno>
<imprint><biblScope unit="vol">79</biblScope>
<biblScope unit="issue">6</biblScope>
<biblScope unit="page" from="724">724</biblScope>
<biblScope unit="page" to="733">733</biblScope>
<biblScope unit="page-count">10</biblScope>
<publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2007-06">2007-06</date>
</imprint>
<idno type="ISSN">0146-6615</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0146-6615</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>African americans</term>
<term>Allele</term>
<term>Allele frequency</term>
<term>Allelic frequency</term>
<term>Amino acids</term>
<term>Assay</term>
<term>Binding prediction programs</term>
<term>Blood donors</term>
<term>Candotti</term>
<term>Cellular</term>
<term>Cellular responses</term>
<term>Chronic hepatitis</term>
<term>Chronic infection</term>
<term>Chronic infections</term>
<term>Clear difference</term>
<term>Consensus sequences</term>
<term>Donor</term>
<term>Donor samples</term>
<term>Elispot</term>
<term>Elispot assay</term>
<term>Epitope</term>
<term>Genotype</term>
<term>Ghanaian</term>
<term>Ghanaian blood donors</term>
<term>Ghanaian donors</term>
<term>Ghanaian samples</term>
<term>Ghanaian subjects</term>
<term>Hepatitis</term>
<term>Hepatocellular carcinoma</term>
<term>High frequency</term>
<term>High rate</term>
<term>Host factors</term>
<term>Infection</term>
<term>Irish study</term>
<term>Killer cell receptor</term>
<term>National blood service</term>
<term>Negative control</term>
<term>Negative samples</term>
<term>Ns5b</term>
<term>Ns5b epitopes</term>
<term>Ns5b genotype</term>
<term>Ns5b sequence</term>
<term>Ns5b sequences</term>
<term>Odds ratio</term>
<term>Odds ratios</term>
<term>Overnight incubation</term>
<term>Pbmcs</term>
<term>Peripheral blood</term>
<term>Plasma samples</term>
<term>Present study</term>
<term>Protective effect</term>
<term>Rapid test</term>
<term>Reactive</term>
<term>Reactive band</term>
<term>Reactive samples</term>
<term>Recombinant</term>
<term>Recombinant core</term>
<term>Recombinant genotype</term>
<term>Recombinant proteins</term>
<term>Single source</term>
<term>Small number</term>
<term>Standard deviations</term>
<term>Strong association</term>
<term>Viral</term>
<term>Viral clearance</term>
<term>Viral load</term>
<term>Viral markers</term>
<term>Virol</term>
<term>Virus genotype</term>
<term>Virus infection</term>
<term>West africa</term>
<term>Western blot</term>
</keywords>
<keywords scheme="Teeft" xml:lang="en"><term>African americans</term>
<term>Allele</term>
<term>Allele frequency</term>
<term>Allelic frequency</term>
<term>Amino acids</term>
<term>Assay</term>
<term>Binding prediction programs</term>
<term>Blood donors</term>
<term>Candotti</term>
<term>Cellular</term>
<term>Cellular responses</term>
<term>Chronic hepatitis</term>
<term>Chronic infection</term>
<term>Chronic infections</term>
<term>Clear difference</term>
<term>Consensus sequences</term>
<term>Donor</term>
<term>Donor samples</term>
<term>Elispot</term>
<term>Elispot assay</term>
<term>Epitope</term>
<term>Genotype</term>
<term>Ghanaian</term>
<term>Ghanaian blood donors</term>
<term>Ghanaian donors</term>
<term>Ghanaian samples</term>
<term>Ghanaian subjects</term>
<term>Hepatitis</term>
<term>Hepatocellular carcinoma</term>
<term>High frequency</term>
<term>High rate</term>
<term>Host factors</term>
<term>Infection</term>
<term>Irish study</term>
<term>Killer cell receptor</term>
<term>National blood service</term>
<term>Negative control</term>
<term>Negative samples</term>
<term>Ns5b</term>
<term>Ns5b epitopes</term>
<term>Ns5b genotype</term>
<term>Ns5b sequence</term>
<term>Ns5b sequences</term>
<term>Odds ratio</term>
<term>Odds ratios</term>
<term>Overnight incubation</term>
<term>Pbmcs</term>
<term>Peripheral blood</term>
<term>Plasma samples</term>
<term>Present study</term>
<term>Protective effect</term>
<term>Rapid test</term>
<term>Reactive</term>
<term>Reactive band</term>
<term>Reactive samples</term>
<term>Recombinant</term>
<term>Recombinant core</term>
<term>Recombinant genotype</term>
<term>Recombinant proteins</term>
<term>Single source</term>
<term>Small number</term>
<term>Standard deviations</term>
<term>Strong association</term>
<term>Viral</term>
<term>Viral clearance</term>
<term>Viral load</term>
<term>Viral markers</term>
<term>Virol</term>
<term>Virus genotype</term>
<term>Virus infection</term>
<term>West africa</term>
<term>Western blot</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Recovery from Hepatitis C virus (HCV) infection is considered infrequent (<20%) in western populations but reaches 50% in West Africa where genotype 2 infection is predominant. To investigate the role of cellular immune responses and host genetics in this phenomenon, samples from 104 Ghanaian blood donors reactive with anti‐HCV assays were collected between 2000 and 2005. HCV antibody was confirmed by Western blot using genotype 2 recombinant core, E2 and NS3 proteins. Viral load and genotype were determined. Samples were stratified into 37 chronic, 35 recovered infections and 32 false positive. Eighty‐one percentage of subjects with chronic infection (RNA positive) carried genotype 2 HCV. Cellular immune response was investigated in 35 frozen peripheral blood mononuclear cell (PBMC) samples suitable for interferon‐gamma ELISPOT assay. Twelve out of 24 confirmed recovered, 1 out of 5 chronically infected and none of the 6 false‐positive controls reacted to recombinant proteins. HLA‐A, ‐B and ‐DR types were determined by DNA methodology. HLA‐B*57 was significantly more frequent in the group which had recovered from HCV infection compared with chronically infected subjects (P = 0.0053, OR = 8.02). In conclusion, it is hypothesized that the dominance of genotype 2 HCV strains may be an important factor explaining the high rate of recovery from HCV infections in Ghana via an efficient contribution of HLA‐B*57 which is relatively frequent in the population. J. Med. Virol. 79: 724–733, 2007. © 2007 Wiley‐Liss, Inc.</div>
</front>
</TEI>
<istex><corpusName>wiley</corpusName>
<keywords><teeft><json:string>genotype</json:string>
<json:string>allele</json:string>
<json:string>reactive</json:string>
<json:string>ns5b</json:string>
<json:string>ghanaian</json:string>
<json:string>virol</json:string>
<json:string>viral</json:string>
<json:string>recombinant</json:string>
<json:string>candotti</json:string>
<json:string>epitope</json:string>
<json:string>pbmcs</json:string>
<json:string>elispot</json:string>
<json:string>western blot</json:string>
<json:string>chronic infection</json:string>
<json:string>elispot assay</json:string>
<json:string>present study</json:string>
<json:string>virus infection</json:string>
<json:string>assay</json:string>
<json:string>donor</json:string>
<json:string>viral clearance</json:string>
<json:string>recombinant proteins</json:string>
<json:string>west africa</json:string>
<json:string>ghanaian blood donors</json:string>
<json:string>national blood service</json:string>
<json:string>donor samples</json:string>
<json:string>irish study</json:string>
<json:string>blood donors</json:string>
<json:string>infection</json:string>
<json:string>hepatitis</json:string>
<json:string>standard deviations</json:string>
<json:string>odds ratio</json:string>
<json:string>high rate</json:string>
<json:string>african americans</json:string>
<json:string>reactive band</json:string>
<json:string>single source</json:string>
<json:string>amino acids</json:string>
<json:string>small number</json:string>
<json:string>chronic hepatitis</json:string>
<json:string>cellular</json:string>
<json:string>rapid test</json:string>
<json:string>host factors</json:string>
<json:string>recombinant core</json:string>
<json:string>reactive samples</json:string>
<json:string>peripheral blood</json:string>
<json:string>negative samples</json:string>
<json:string>plasma samples</json:string>
<json:string>clear difference</json:string>
<json:string>recombinant genotype</json:string>
<json:string>ns5b sequences</json:string>
<json:string>ns5b sequence</json:string>
<json:string>consensus sequences</json:string>
<json:string>negative control</json:string>
<json:string>high frequency</json:string>
<json:string>virus genotype</json:string>
<json:string>protective effect</json:string>
<json:string>ghanaian samples</json:string>
<json:string>chronic infections</json:string>
<json:string>allelic frequency</json:string>
<json:string>ghanaian subjects</json:string>
<json:string>odds ratios</json:string>
<json:string>viral load</json:string>
<json:string>allele frequency</json:string>
<json:string>strong association</json:string>
<json:string>killer cell receptor</json:string>
<json:string>hepatocellular carcinoma</json:string>
<json:string>ghanaian donors</json:string>
<json:string>ns5b epitopes</json:string>
<json:string>ns5b genotype</json:string>
<json:string>binding prediction programs</json:string>
<json:string>cellular responses</json:string>
<json:string>viral markers</json:string>
<json:string>overnight incubation</json:string>
</teeft>
</keywords>
<author><json:item><name>Wing Chia‐Ming Chuang</name>
<affiliations><json:string>Department of Haematology, University of Cambridge, Cambridge, UK</json:string>
</affiliations>
</json:item>
<json:item><name>Francis Sarkodie</name>
<affiliations><json:string>Transfusion Medicine Unit, Department of Medicine, Komfo Anokye Teaching Hospital, Kumasi, Ghana</json:string>
</affiliations>
</json:item>
<json:item><name>Colin J. Brown</name>
<affiliations><json:string>Department of Histocompatibility & Immunogenetics, National Blood Service, Colindale, London, UK</json:string>
</affiliations>
</json:item>
<json:item><name>Shirley Owusu‐Ofori</name>
<affiliations><json:string>Transfusion Medicine Unit, Department of Medicine, Komfo Anokye Teaching Hospital, Kumasi, Ghana</json:string>
</affiliations>
</json:item>
<json:item><name>Juliette Brown</name>
<affiliations><json:string>Department of Histocompatibility & Immunogenetics, National Blood Service, Colindale, London, UK</json:string>
</affiliations>
</json:item>
<json:item><name>Chengyao Li</name>
<affiliations><json:string>National Blood Service, Cambridge, UK</json:string>
</affiliations>
</json:item>
<json:item><name>Cristina Navarrete</name>
<affiliations><json:string>Department of Histocompatibility & Immunogenetics, National Blood Service, Colindale, London, UK</json:string>
</affiliations>
</json:item>
<json:item><name>Paul Klenerman</name>
<affiliations><json:string>Nuffield Department of Medicine, University of Oxford, Oxford, UK</json:string>
</affiliations>
</json:item>
<json:item><name>Jean‐Pierre Allain</name>
<affiliations><json:string>Department of Haematology, University of Cambridge, Cambridge, UK</json:string>
<json:string>Division of Transfusion Medicine, Cambridge Blood Centre, Long Road, Cambridge CB2 2PT, UK.===</json:string>
</affiliations>
</json:item>
</author>
<subject><json:item><lang><json:string>eng</json:string>
</lang>
<value>HCV</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>HCV genotype 2</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>HCV recovery</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>Ghana</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>HLA‐B57</value>
</json:item>
</subject>
<articleId><json:string>JMV20848</json:string>
</articleId>
<language><json:string>eng</json:string>
</language>
<originalGenre><json:string>article</json:string>
</originalGenre>
<abstract>Recovery from Hepatitis C virus (HCV) infection is considered infrequent (>20%) in western populations but reaches 50% in West Africa where genotype 2 infection is predominant. To investigate the role of cellular immune responses and host genetics in this phenomenon, samples from 104 Ghanaian blood donors reactive with anti‐HCV assays were collected between 2000 and 2005. HCV antibody was confirmed by Western blot using genotype 2 recombinant core, E2 and NS3 proteins. Viral load and genotype were determined. Samples were stratified into 37 chronic, 35 recovered infections and 32 false positive. Eighty‐one percentage of subjects with chronic infection (RNA positive) carried genotype 2 HCV. Cellular immune response was investigated in 35 frozen peripheral blood mononuclear cell (PBMC) samples suitable for interferon‐gamma ELISPOT assay. Twelve out of 24 confirmed recovered, 1 out of 5 chronically infected and none of the 6 false‐positive controls reacted to recombinant proteins. HLA‐A, ‐B and ‐DR types were determined by DNA methodology. HLA‐B*57 was significantly more frequent in the group which had recovered from HCV infection compared with chronically infected subjects (P = 0.0053, OR = 8.02). In conclusion, it is hypothesized that the dominance of genotype 2 HCV strains may be an important factor explaining the high rate of recovery from HCV infections in Ghana via an efficient contribution of HLA‐B*57 which is relatively frequent in the population. J. Med. Virol. 79: 724–733, 2007. © 2007 Wiley‐Liss, Inc.</abstract>
<qualityIndicators><score>7.748</score>
<pdfVersion>1.3</pdfVersion>
<pdfPageSize>594 x 792 pts</pdfPageSize>
<refBibsNative>true</refBibsNative>
<abstractCharCount>1534</abstractCharCount>
<pdfWordCount>5927</pdfWordCount>
<pdfCharCount>38706</pdfCharCount>
<pdfPageCount>10</pdfPageCount>
<abstractWordCount>229</abstractWordCount>
</qualityIndicators>
<title>Protective effect of HLA‐B57 on HCV genotype 2 infection in a West African population</title>
<genre><json:string>article</json:string>
</genre>
<host><title>Journal of Medical Virology</title>
<language><json:string>unknown</json:string>
</language>
<doi><json:string>10.1002/(ISSN)1096-9071</json:string>
</doi>
<issn><json:string>0146-6615</json:string>
</issn>
<eissn><json:string>1096-9071</json:string>
</eissn>
<publisherId><json:string>JMV</json:string>
</publisherId>
<volume>79</volume>
<issue>6</issue>
<pages><first>724</first>
<last>733</last>
<total>10</total>
</pages>
<genre><json:string>journal</json:string>
</genre>
<subject><json:item><value>Research Article</value>
</json:item>
</subject>
</host>
<categories><wos><json:string>science</json:string>
<json:string>virology</json:string>
</wos>
<scienceMetrix><json:string>health sciences</json:string>
<json:string>biomedical research</json:string>
<json:string>virology</json:string>
</scienceMetrix>
</categories>
<publicationDate>2007</publicationDate>
<copyrightDate>2007</copyrightDate>
<doi><json:string>10.1002/jmv.20848</json:string>
</doi>
<id>95373D3160E2A7717E344A8120A43D3C167CE4F4</id>
<score>1</score>
<fulltext><json:item><extension>pdf</extension>
<original>true</original>
<mimetype>application/pdf</mimetype>
<uri>https://api.istex.fr/document/95373D3160E2A7717E344A8120A43D3C167CE4F4/fulltext/pdf</uri>
</json:item>
<json:item><extension>zip</extension>
<original>false</original>
<mimetype>application/zip</mimetype>
<uri>https://api.istex.fr/document/95373D3160E2A7717E344A8120A43D3C167CE4F4/fulltext/zip</uri>
</json:item>
<istex:fulltextTEI uri="https://api.istex.fr/document/95373D3160E2A7717E344A8120A43D3C167CE4F4/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Protective effect of HLA‐B57 on HCV genotype 2 infection in a West African population</title>
</titleStmt>
<publicationStmt><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<availability><licence>Copyright © 2007 Wiley‐Liss, Inc.</licence>
</availability>
<date type="published" when="2007-06"></date>
</publicationStmt>
<notesStmt><note type="content-type" subtype="article" source="article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</note>
<note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note>
</notesStmt>
<sourceDesc><biblStruct type="article"><analytic><title level="a" type="main" xml:lang="en">Protective effect of HLA‐B57 on HCV genotype 2 infection in a West African population</title>
<title level="a" type="short" xml:lang="en">Recovery From Genotype 2 HCV is Associated With HLA‐B57</title>
<author xml:id="author-0000"><persName><forename type="first">Wing Chia‐Ming</forename>
<surname>Chuang</surname>
</persName>
<affiliation>Department of Haematology, University of Cambridge, Cambridge, UK<address><country key="GB"></country>
</address>
</affiliation>
</author>
<author xml:id="author-0001"><persName><forename type="first">Francis</forename>
<surname>Sarkodie</surname>
</persName>
<affiliation>Transfusion Medicine Unit, Department of Medicine, Komfo Anokye Teaching Hospital, Kumasi, Ghana<address><country key="GH"></country>
</address>
</affiliation>
</author>
<author xml:id="author-0002"><persName><forename type="first">Colin J.</forename>
<surname>Brown</surname>
</persName>
<affiliation>Department of Histocompatibility & Immunogenetics, National Blood Service, Colindale, London, UK<address><country key="GB"></country>
</address>
</affiliation>
</author>
<author xml:id="author-0003"><persName><forename type="first">Shirley</forename>
<surname>Owusu‐Ofori</surname>
</persName>
<affiliation>Transfusion Medicine Unit, Department of Medicine, Komfo Anokye Teaching Hospital, Kumasi, Ghana<address><country key="GH"></country>
</address>
</affiliation>
</author>
<author xml:id="author-0004"><persName><forename type="first">Juliette</forename>
<surname>Brown</surname>
</persName>
<affiliation>Department of Histocompatibility & Immunogenetics, National Blood Service, Colindale, London, UK<address><country key="GB"></country>
</address>
</affiliation>
</author>
<author xml:id="author-0005"><persName><forename type="first">Chengyao</forename>
<surname>Li</surname>
</persName>
<affiliation>National Blood Service, Cambridge, UK<address><country key="GB"></country>
</address>
</affiliation>
</author>
<author xml:id="author-0006"><persName><forename type="first">Cristina</forename>
<surname>Navarrete</surname>
</persName>
<affiliation>Department of Histocompatibility & Immunogenetics, National Blood Service, Colindale, London, UK<address><country key="GB"></country>
</address>
</affiliation>
</author>
<author xml:id="author-0007"><persName><forename type="first">Paul</forename>
<surname>Klenerman</surname>
</persName>
<affiliation>Nuffield Department of Medicine, University of Oxford, Oxford, UK<address><country key="GB"></country>
</address>
</affiliation>
</author>
<author xml:id="author-0008" role="corresp"><persName><forename type="first">Jean‐Pierre</forename>
<surname>Allain</surname>
</persName>
<email>jpa1000@cam.ac.uk</email>
<affiliation>Department of Haematology, University of Cambridge, Cambridge, UK<address><country key="GB"></country>
</address>
</affiliation>
<affiliation>Division of Transfusion Medicine, Cambridge Blood Centre, Long Road, Cambridge CB2 2PT, UK.===</affiliation>
</author>
<idno type="istex">95373D3160E2A7717E344A8120A43D3C167CE4F4</idno>
<idno type="DOI">10.1002/jmv.20848</idno>
<idno type="unit">JMV20848</idno>
<idno type="toTypesetVersion">file:JMV.JMV20848.pdf</idno>
</analytic>
<monogr><title level="j" type="main">Journal of Medical Virology</title>
<title level="j" type="alt">JOURNAL OF MEDICAL VIROLOGY</title>
<idno type="pISSN">0146-6615</idno>
<idno type="eISSN">1096-9071</idno>
<idno type="book-DOI">10.1002/(ISSN)1096-9071</idno>
<idno type="book-part-DOI">10.1002/jmv.v79:6</idno>
<idno type="product">JMV</idno>
<imprint><biblScope unit="vol">79</biblScope>
<biblScope unit="issue">6</biblScope>
<biblScope unit="page" from="724">724</biblScope>
<biblScope unit="page" to="733">733</biblScope>
<biblScope unit="page-count">10</biblScope>
<publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2007-06"></date>
</imprint>
</monogr>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><abstract xml:lang="en" style="main"><head>Abstract</head>
<p>Recovery from <hi rend="italic">Hepatitis C virus</hi>
 (HCV) infection is considered infrequent (<20%) in western populations but reaches 50% in West Africa where genotype 2 infection is predominant. To investigate the role of cellular immune responses and host genetics in this phenomenon, samples from 104 Ghanaian blood donors reactive with anti‐HCV assays were collected between 2000 and 2005. HCV antibody was confirmed by Western blot using genotype 2 recombinant core, E2 and NS3 proteins. Viral load and genotype were determined. Samples were stratified into 37 chronic, 35 recovered infections and 32 false positive. Eighty‐one percentage of subjects with chronic infection (RNA positive) carried genotype 2 HCV. Cellular immune response was investigated in 35 frozen peripheral blood mononuclear cell (PBMC) samples suitable for interferon‐gamma ELISPOT assay. Twelve out of 24 confirmed recovered, 1 out of 5 chronically infected and none of the 6 false‐positive controls reacted to recombinant proteins. HLA‐A, ‐B and ‐DR types were determined by DNA methodology. HLA‐B*57 was significantly more frequent in the group which had recovered from HCV infection compared with chronically infected subjects (<hi rend="italic">P</hi>
 = 0.0053, OR = 8.02). In conclusion, it is hypothesized that the dominance of genotype 2 HCV strains may be an important factor explaining the high rate of recovery from HCV infections in Ghana via an efficient contribution of HLA‐B*57 which is relatively frequent in the population. J. Med. Virol. 79: 724–733, 2007. © 2007 Wiley‐Liss, Inc.</p>
</abstract>
<textClass><keywords xml:lang="en"><term xml:id="kwd1">HCV</term>
<term xml:id="kwd2">HCV genotype 2</term>
<term xml:id="kwd3">HCV recovery</term>
<term xml:id="kwd4">Ghana</term>
<term xml:id="kwd5">HLA‐B57</term>
</keywords>
<classCode scheme="articleCategory">Research Article</classCode>
</textClass>
<langUsage><language ident="EN"></language>
</langUsage>
</profileDesc>
</teiHeader>
</istex:fulltextTEI>
<json:item><extension>txt</extension>
<original>false</original>
<mimetype>text/plain</mimetype>
<uri>https://api.istex.fr/document/95373D3160E2A7717E344A8120A43D3C167CE4F4/fulltext/txt</uri>
</json:item>
</fulltext>
<metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration>
<istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName>
<publisherLoc>Hoboken</publisherLoc>
</publisherInfo>
<doi registered="yes">10.1002/(ISSN)1096-9071</doi>
<issn type="print">0146-6615</issn>
<issn type="electronic">1096-9071</issn>
<idGroup><id type="product" value="JMV"></id>
</idGroup>
<titleGroup><title type="main" xml:lang="en" sort="JOURNAL OF MEDICAL VIROLOGY">Journal of Medical Virology</title>
<title type="short">J. Med. Virol.</title>
</titleGroup>
</publicationMeta>
<publicationMeta level="part" position="60"><doi origin="wiley" registered="yes">10.1002/jmv.v79:6</doi>
<numberingGroup><numbering type="journalVolume" number="79">79</numbering>
<numbering type="journalIssue">6</numbering>
</numberingGroup>
<coverDate startDate="2007-06">June 2007</coverDate>
</publicationMeta>
<publicationMeta level="unit" type="article" position="100" status="forIssue"><doi origin="wiley" registered="yes">10.1002/jmv.20848</doi>
<idGroup><id type="unit" value="JMV20848"></id>
</idGroup>
<countGroup><count type="pageTotal" number="10"></count>
</countGroup>
<titleGroup><title type="articleCategory">Research Article</title>
</titleGroup>
<copyright ownership="publisher">Copyright © 2007 Wiley‐Liss, Inc.</copyright>
<eventGroup><event type="manuscriptAccepted" date="2007-02-16"></event>
<event type="firstOnline" date="2007-04-24"></event>
<event type="publishedOnlineFinalForm" date="2007-04-24"></event>
<event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.4.7 mode:FullText source:HeaderRef result:HeaderRef" date="2011-02-24"></event>
<event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:4.0.1" date="2014-03-20"></event>
<event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-30"></event>
</eventGroup>
<numberingGroup><numbering type="pageFirst">724</numbering>
<numbering type="pageLast">733</numbering>
</numberingGroup>
<correspondenceTo>Division of Transfusion Medicine, Cambridge Blood Centre, Long Road, Cambridge CB2 2PT, UK.===</correspondenceTo>
<linkGroup><link type="toTypesetVersion" href="file:JMV.JMV20848.pdf"></link>
</linkGroup>
</publicationMeta>
<contentMeta><countGroup><count type="figureTotal" number="2"></count>
<count type="tableTotal" number="2"></count>
<count type="referenceTotal" number="30"></count>
<count type="wordTotal" number="1232"></count>
</countGroup>
<titleGroup><title type="main" xml:lang="en">Protective effect of HLA‐B57 on HCV genotype 2 infection in a West African population</title>
<title type="short" xml:lang="en">Recovery From Genotype 2 HCV is Associated With HLA‐B57</title>
</titleGroup>
<creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Wing Chia‐Ming</givenNames>
<familyName>Chuang</familyName>
</personName>
</creator>
<creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Francis</givenNames>
<familyName>Sarkodie</familyName>
</personName>
</creator>
<creator xml:id="au3" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Colin J.</givenNames>
<familyName>Brown</familyName>
</personName>
</creator>
<creator xml:id="au4" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Shirley</givenNames>
<familyName>Owusu‐Ofori</familyName>
</personName>
</creator>
<creator xml:id="au5" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Juliette</givenNames>
<familyName>Brown</familyName>
</personName>
</creator>
<creator xml:id="au6" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Chengyao</givenNames>
<familyName>Li</familyName>
</personName>
</creator>
<creator xml:id="au7" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Cristina</givenNames>
<familyName>Navarrete</familyName>
</personName>
</creator>
<creator xml:id="au8" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Paul</givenNames>
<familyName>Klenerman</familyName>
</personName>
</creator>
<creator xml:id="au9" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Jean‐Pierre</givenNames>
<familyName>Allain</familyName>
</personName>
<contactDetails><email>jpa1000@cam.ac.uk</email>
</contactDetails>
</creator>
</creators>
<affiliationGroup><affiliation xml:id="af1" countryCode="GB" type="organization"><unparsedAffiliation>Department of Haematology, University of Cambridge, Cambridge, UK</unparsedAffiliation>
</affiliation>
<affiliation xml:id="af2" countryCode="GH" type="organization"><unparsedAffiliation>Transfusion Medicine Unit, Department of Medicine, Komfo Anokye Teaching Hospital, Kumasi, Ghana</unparsedAffiliation>
</affiliation>
<affiliation xml:id="af3" countryCode="GB" type="organization"><unparsedAffiliation>Department of Histocompatibility & Immunogenetics, National Blood Service, Colindale, London, UK</unparsedAffiliation>
</affiliation>
<affiliation xml:id="af4" countryCode="GB" type="organization"><unparsedAffiliation>National Blood Service, Cambridge, UK</unparsedAffiliation>
</affiliation>
<affiliation xml:id="af5" countryCode="GB" type="organization"><unparsedAffiliation>Nuffield Department of Medicine, University of Oxford, Oxford, UK</unparsedAffiliation>
</affiliation>
</affiliationGroup>
<keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">HCV</keyword>
<keyword xml:id="kwd2">HCV genotype 2</keyword>
<keyword xml:id="kwd3">HCV recovery</keyword>
<keyword xml:id="kwd4">Ghana</keyword>
<keyword xml:id="kwd5">HLA‐B57</keyword>
</keywordGroup>
<fundingInfo><fundingAgency>National Blood Service</fundingAgency>
</fundingInfo>
<abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title>
<p>Recovery from <i>Hepatitis C virus</i>
 (HCV) infection is considered infrequent (<20%) in western populations but reaches 50% in West Africa where genotype 2 infection is predominant. To investigate the role of cellular immune responses and host genetics in this phenomenon, samples from 104 Ghanaian blood donors reactive with anti‐HCV assays were collected between 2000 and 2005. HCV antibody was confirmed by Western blot using genotype 2 recombinant core, E2 and NS3 proteins. Viral load and genotype were determined. Samples were stratified into 37 chronic, 35 recovered infections and 32 false positive. Eighty‐one percentage of subjects with chronic infection (RNA positive) carried genotype 2 HCV. Cellular immune response was investigated in 35 frozen peripheral blood mononuclear cell (PBMC) samples suitable for interferon‐gamma ELISPOT assay. Twelve out of 24 confirmed recovered, 1 out of 5 chronically infected and none of the 6 false‐positive controls reacted to recombinant proteins. HLA‐A, ‐B and ‐DR types were determined by DNA methodology. HLA‐B*57 was significantly more frequent in the group which had recovered from HCV infection compared with chronically infected subjects (<i>P</i>
 = 0.0053, OR = 8.02). In conclusion, it is hypothesized that the dominance of genotype 2 HCV strains may be an important factor explaining the high rate of recovery from HCV infections in Ghana via an efficient contribution of HLA‐B*57 which is relatively frequent in the population. J. Med. Virol. 79: 724–733, 2007. © 2007 Wiley‐Liss, Inc.</p>
</abstract>
</abstractGroup>
</contentMeta>
</header>
</component>
</istex:document>
</istex:metadataXml>
<mods version="3.6"><titleInfo lang="en"><title>Protective effect of HLA‐B57 on HCV genotype 2 infection in a West African population</title>
</titleInfo>
<titleInfo type="abbreviated" lang="en"><title>Recovery From Genotype 2 HCV is Associated With HLA‐B57</title>
</titleInfo>
<titleInfo type="alternative" contentType="CDATA" lang="en"><title>Protective effect of HLA‐B57 on HCV genotype 2 infection in a West African population</title>
</titleInfo>
<name type="personal"><namePart type="given">Wing Chia‐Ming</namePart>
<namePart type="family">Chuang</namePart>
<affiliation>Department of Haematology, University of Cambridge, Cambridge, UK</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Francis</namePart>
<namePart type="family">Sarkodie</namePart>
<affiliation>Transfusion Medicine Unit, Department of Medicine, Komfo Anokye Teaching Hospital, Kumasi, Ghana</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Colin J.</namePart>
<namePart type="family">Brown</namePart>
<affiliation>Department of Histocompatibility & Immunogenetics, National Blood Service, Colindale, London, UK</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Shirley</namePart>
<namePart type="family">Owusu‐Ofori</namePart>
<affiliation>Transfusion Medicine Unit, Department of Medicine, Komfo Anokye Teaching Hospital, Kumasi, Ghana</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Juliette</namePart>
<namePart type="family">Brown</namePart>
<affiliation>Department of Histocompatibility & Immunogenetics, National Blood Service, Colindale, London, UK</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Chengyao</namePart>
<namePart type="family">Li</namePart>
<affiliation>National Blood Service, Cambridge, UK</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Cristina</namePart>
<namePart type="family">Navarrete</namePart>
<affiliation>Department of Histocompatibility & Immunogenetics, National Blood Service, Colindale, London, UK</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Paul</namePart>
<namePart type="family">Klenerman</namePart>
<affiliation>Nuffield Department of Medicine, University of Oxford, Oxford, UK</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Jean‐Pierre</namePart>
<namePart type="family">Allain</namePart>
<affiliation>Department of Haematology, University of Cambridge, Cambridge, UK</affiliation>
<affiliation>Division of Transfusion Medicine, Cambridge Blood Centre, Long Road, Cambridge CB2 2PT, UK.===</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<typeOfResource>text</typeOfResource>
<genre type="article" displayLabel="article"></genre>
<originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<place><placeTerm type="text">Hoboken</placeTerm>
</place>
<dateIssued encoding="w3cdtf">2007-06</dateIssued>
<dateValid encoding="w3cdtf">2007-02-16</dateValid>
<copyrightDate encoding="w3cdtf">2007</copyrightDate>
</originInfo>
<language><languageTerm type="code" authority="rfc3066">en</languageTerm>
<languageTerm type="code" authority="iso639-2b">eng</languageTerm>
</language>
<physicalDescription><internetMediaType>text/html</internetMediaType>
<extent unit="figures">2</extent>
<extent unit="tables">2</extent>
<extent unit="references">30</extent>
<extent unit="words">1232</extent>
</physicalDescription>
<abstract lang="en">Recovery from Hepatitis C virus (HCV) infection is considered infrequent (<20%) in western populations but reaches 50% in West Africa where genotype 2 infection is predominant. To investigate the role of cellular immune responses and host genetics in this phenomenon, samples from 104 Ghanaian blood donors reactive with anti‐HCV assays were collected between 2000 and 2005. HCV antibody was confirmed by Western blot using genotype 2 recombinant core, E2 and NS3 proteins. Viral load and genotype were determined. Samples were stratified into 37 chronic, 35 recovered infections and 32 false positive. Eighty‐one percentage of subjects with chronic infection (RNA positive) carried genotype 2 HCV. Cellular immune response was investigated in 35 frozen peripheral blood mononuclear cell (PBMC) samples suitable for interferon‐gamma ELISPOT assay. Twelve out of 24 confirmed recovered, 1 out of 5 chronically infected and none of the 6 false‐positive controls reacted to recombinant proteins. HLA‐A, ‐B and ‐DR types were determined by DNA methodology. HLA‐B*57 was significantly more frequent in the group which had recovered from HCV infection compared with chronically infected subjects (P = 0.0053, OR = 8.02). In conclusion, it is hypothesized that the dominance of genotype 2 HCV strains may be an important factor explaining the high rate of recovery from HCV infections in Ghana via an efficient contribution of HLA‐B*57 which is relatively frequent in the population. J. Med. Virol. 79: 724–733, 2007. © 2007 Wiley‐Liss, Inc.</abstract>
<note type="funding">National Blood Service</note>
<subject lang="en"><genre>keywords</genre>
<topic>HCV</topic>
<topic>HCV genotype 2</topic>
<topic>HCV recovery</topic>
<topic>Ghana</topic>
<topic>HLA‐B57</topic>
</subject>
<relatedItem type="host"><titleInfo><title>Journal of Medical Virology</title>
</titleInfo>
<titleInfo type="abbreviated"><title>J. Med. Virol.</title>
</titleInfo>
<genre type="journal">journal</genre>
<subject><genre>article-category</genre>
<topic>Research Article</topic>
</subject>
<identifier type="ISSN">0146-6615</identifier>
<identifier type="eISSN">1096-9071</identifier>
<identifier type="DOI">10.1002/(ISSN)1096-9071</identifier>
<identifier type="PublisherID">JMV</identifier>
<part><date>2007</date>
<detail type="volume"><caption>vol.</caption>
<number>79</number>
</detail>
<detail type="issue"><caption>no.</caption>
<number>6</number>
</detail>
<extent unit="pages"><start>724</start>
<end>733</end>
<total>10</total>
</extent>
</part>
</relatedItem>
<identifier type="istex">95373D3160E2A7717E344A8120A43D3C167CE4F4</identifier>
<identifier type="DOI">10.1002/jmv.20848</identifier>
<identifier type="ArticleID">JMV20848</identifier>
<accessCondition type="use and reproduction" contentType="copyright">Copyright © 2007 Wiley‐Liss, Inc.</accessCondition>
<recordInfo><recordContentSource>WILEY</recordContentSource>
<recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin>
</recordInfo>
</mods>
</metadata>
<serie></serie>
</istex>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/Istex/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000830 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000830 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    SidaGhanaV1
   |flux=    Istex
   |étape=   Corpus
   |type=    RBID
   |clé=     ISTEX:95373D3160E2A7717E344A8120A43D3C167CE4F4
   |texte=   Protective effect of HLA‐B57 on HCV genotype 2 infection in a West African population
}}

This area was generated with Dilib version V0.6.31.
Data generation: Tue Nov 7 18:07:38 2017. Site generation: Tue Mar 5 15:01:57 2024

	Le SIDA au Ghana (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Le SIDA au Ghana (serveur d'exploration)

Protective effect of HLA‐B57 on HCV genotype 2 infection in a West African population

Protective effect of HLA‐B57 on HCV genotype 2 infection in a West African population

Source :

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri